sciencenewsnet.in

Biomarker Uncovered by Roswell Park Team Identifies NET Patients Likely to Have Blood Side Effects from PRRT

June 9, 2021 sarah JonasResearch Results

New work from a team at Roswell Park Comprehensive Cancer Center will help guide the care of patients with neuroendocrine tumors, or NETs. In a poster presentation at the American Society of Clinical Oncology (ASCO) virtual Annual Meeting 2021, Abhay Singh, MD, MPH, and colleagues outline their discovery of a potential biomarker to predict which patients are likely to experience blood toxicity side effects from a new targeted radiation treatment, peptide receptor radionuclide therapy (PRRT).

Research Group Identifies Potential Therapeutic Target for Lupus

March 26, 2021 sarah JonasResearch Results

Inhibiting IRE1α, a molecule activated by the endoplasmic reticulum in neutrophils, counters disease progression in lupus mice.

Roswell Park Studies Highlight Emerging Treatment Options for Neuroendocrine Tumors

July 14, 2020 sarah JonasResearch Results

Two new studies led by Renuka Iyer, MD, Section Chief for Gastrointestinal Oncology at Roswell Park Comprehensive Cancer Center, highlight possible new treatment options for patients with neuroendocrine tumors (NETs) — a rare and hard-to-treat cancer.